Creative Biotherapeutics, LLC announced continued progress in the preclinical development of CBT300, an investigational biologic therapeutic candidate. The program is being advanced through research, validation, and regulatory preparation focused on mechanisms associated with drug resistance, immune evasion, recurrence, and metastasis. The company is led by clinician Anita Davidson and biochemist Dr. Don Davidson, whose work is informed by decades of patient care and drug development experience.
For Anita Davidson, the motivation stems directly from clinical reality. She recently lost a sixteen-year-old patient to a brain cancer that returned rapidly despite treatment. ‘There are losses that stay with you,’ Davidson said. ‘You remember the families, the hopes, and the urgency. That child is a reason I keep working.’ Later, she added, ‘We just could not watch another child die.’ The company has not announced initial clinical indications for CBT300.
Dr. Don Davidson explained that the development efforts are guided by a focus on biological mechanisms contributing to treatment failure. ‘Cancer outcomes are often shaped by recurrence and resistance,’ he said. ‘Our development work focuses on mechanisms associated with relapse and treatment escape so future therapies can be evaluated with that reality in mind.’ CBT300 is being developed as a multi-mechanism biologic candidate intended to be evaluated for its potential to interfere with drug-resistance pathways, immune-evasion mechanisms, and cellular processes linked to recurrence and metastasis.
The company stated that research and validation are ongoing, with development decisions guided by a disciplined, evidence-based approach as it progresses through regulatory preparation. Davidson also emphasized tolerability as a key consideration. ‘Patients and families live with the full burden of treatment,’ she said. ‘We want development pathways that respect patients and are guided by real-world experience.’ Creative Biotherapeutics is preparing remaining components required to support advancement toward FDA-regulated clinical trials. ‘We are working diligently toward entering clinical trials,’ Dr. Davidson said. ‘Progress has to be earned through data, discipline, and integrity.’
Creative Biotherapeutics is sharing information publicly to support awareness among patients, clinicians, and the scientific community regarding CBT300. The company welcomes mission-aligned collaboration inquiries related to the responsible development of CBT300 and the advancement of science-driven oncology solutions. For more information, visit the official website. CBT300 is investigational and has not been approved by the U.S. Food and Drug Administration.
This news story relied on content distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Creative Biotherapeutics Advances CBT300, an Investigational Biologic Targeting Cancer Recurrence and Drug Resistance.